PTSD is a severe psychiatric illness characterised by four core symptom clusters: re-experiencing, avoidance, negative cognition and mood and hyperarousal.1 With an estimated lifetime prevalence in community samples of up to 8%, PTSD results in a great deal of personal suffering and escalating social and economic costs.2 Unfortunately, current evidence-based treatments for PTSD leave a high percentage with a significant symptom burden, highlighting the urgent need for novel treatments. The growing acceptance3 of rTMS to the dorsolateral prefrontal cortex (DLPFC) for treatment-resistant MDD has evoked the question of its potential efficacy for PTSD.. To read the full article, log in using your NHS OpenAthens details.